SRG Rat

The SRG (Sprague Dawley, Rag2, Il2rg- "SRG") is a severely immunodeficient inbred rat created through knockout mutations in the Rag2 and Il2rgamma genes, resulting in a deficiency in mature B, T, and NK cells. This severe immunodeficiency, combined with a larger organism size, makes the SRG rat an ideal alternative research model to mice in certain preclinical applications. Origin The SRG rat was transferred from Transposagen to Hera Biolabs in 2016. To Charles River from Hera Biolabs in 2021. Benefits of the SRG Rat for Preclinical Oncology Research High engraftment rates and rapid growth of a variety of human tissues and tumors (for example: VCaP, H358, and HCT116) Severe immunodeficiency ensures high engraftment rates and is amenable to humanization Larger organism size allows larger tumor burden and reduces difficulty of procedures such as catherization and blood collection Larger tumor sizes (up to 10x larger compared to mice) allow for serial tissue sampling throughout the treatment routine from the same animal (more robust sample analysis)